ArticleBMC cardiovascular disorders2025
The association between the monocyte-to-HDL cholesterol ratio and coronary collateral circulation in patients with chronic total occlusion.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary collateral circulation (CCC) plays a crucial role in preserving myocardial perfusion in patients with chronic total occlusion (CTO) of the coronary arteries. However, the extent of collateral vessel development varies widely and cannot be explained solely by anatomical or hemodynamic factors. Systemic inflammation and lipid metabolism are critical modulators of arteriogenesis. The monocyte-to-high-density lipoprotein cholesterol ratio (MHR) has been proposed as a novel biomarker reflecting the balance between proinflammatory activity and anti-atherogenic protection. This study aimed to investigate the relationship between the MHR and the adequacy of the CCC in patients with stable coronary artery disease and angiographically confirmed CTO.
methodsThis retrospective study included 143 patients with stable angina who were diagnosed with at least one CTO lesion via coronary angiography. CCC was assessed via the Rentrop classification and categorized as poor (grades 0-1) or good (grades 2-3). Demographic, clinical, and laboratory data, including monocyte count, HDL cholesterol, and high-sensitivity C-reactive protein (hs-CRP) values, were collected. MHR values were calculated and compared between the groups. Logistic regression and receiver operating characteristic (ROC) curve analyses were performed to identify independent predictors and determine the diagnostic performance of the MHR.
resultsPatients with poor CCCs presented significantly higher MHR values (17.3 ± 4.7 vs. 12.0 ± 4.7, p < 0.001), higher hs-CRP levels, and lower HDL cholesterol concentrations. In the multivariate analysis, both the MHR (adjusted odds ratio [aOR]: 1.283, p < 0.001) and the hs-CRP level (aOR: 4.272, p = 0.009) emerged as independent predictors of poor collateral development. The MHR demonstrated good discriminative performance for poor CCC (AUC = 0.808, 95% CI: 0.735-0.881), with an optimal cutoff value of 13.8 (sensitivity 74%, specificity 71%).
conclusionsAn elevated MHR is significantly associated with poor CCC development in patients with CTO. As a readily available and cost-effective biomarker, it has potential clinical utility for identifying patients at risk of insufficient arteriogenesis. Further prospective studies are needed to validate its prognostic utility and explore its therapeutic implications in ischemic heart disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.